Published on
July 30, 2025
- 13:00 GMT
Diamond Therapeutics initiates dosing in first-ever Phase 2a clinical trial evaluating low-dose psilocybin for anxiety
Double-blind, placebo-controlled study explores daily non-psychedelic doses of psilocybin for individuals with Generalized Anxiety Disorder TORONTO, ONTARIO, CANADA, July 30, 2025 /EINPresswire.com/ -- Diamond Therapeutics Inc. ("Diamond"), a clinical-stage drug development company focused on non-hallucinogenic, psychedelic-based therapies for mental health conditions, in partnership with the Kingston Health Sciences Centre Research Institute (KHSC-RI), today announced the enrollment of the …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...